Brian Woodard

Cooley advised WSO2, a leading provider of application development and identity and access management software to enterprise companies globally, on its agreement to be acquired by EQT’s BPEA Fund VIII (EQT Private Capital Asia).

Cooley advised World View, a leader in stratospheric exploration and flight, on its definitive business combination agreement with publicly traded special purpose acquisition company Leo Holdings Corp. II. The transaction will result in World View becoming a publicly listed company. Partners Alex Kassai, Milson Yu and Miguel Vega led the Cooley team advising World View.

Cooley advised Bonum Therapeutics, a biopharmaceutical company focused on creating highly active and less toxic medicines, on its $93 million Series A financing. Partner Sonya Erickson led the Cooley team advising Bonum Therapeutics.

Cooley advised Helion Energy, a clean energy company committed to creating a new era of plentiful, zero-carbon electricity from fusion, on its $500 million Series E financing round, which also includes an opportunity for an additional $1.7 billion tied to Helion reaching key performance milestones. Lawyers Sonya Erickson, Colleen Badgley, Ashley Brown, Justine Chiu and Jasjit Grewal led the Cooley team advising Helion.

Cooley advised Eliem Therapeutics on its $92 million initial public offering of 7,360,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Eliem Therapeutics, whose securities now trade on the Nasdaq Global Market under the symbol ELYM, is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Partners Alan Hambelton, Sonya Erickson and Stephen Rosen led the Cooley team.